Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MOUNTAIN VIEW, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to...
-
MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common...
-
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock...
-
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection...
-
MOUNTAIN VIEW, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part of...
-
MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from...
-
-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year -- -- Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental...
-
MOUNTAIN VIEW, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2020 financial results will be released after market...
-
-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with topline data from four...
-
MOUNTAIN VIEW, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be released...